Friday, 6 March 2020

Global Cell Counting Market Trend, Industry Overview, Competitive Analysis and Foreseen by 2025

Market Forecast

Cell Counting Market is expected to cross USD 12.57 Billion by 2025 at a CAGR of 5.8%.
Market Synopsis
Cell counting is one of the methods for counting cells in life sciences, including medical diagnosis and treatment. The companies operating in this market acquire both organic and inorganic growth strategies to maintain and develop their positions in the market. The increasing funding for stem cell-based research supports the growth of the market.
Market Influencer
Increasing public-private investments and funding in stem cell-based research impact the growth of the cell counting industry positively.
Market Drivers
  • The increasing use of stem cells in various therapeutics is promoting government and private institutes to raise the funding for more development in this area. For instance, in March 2019, the governing Board of the California Institute for Regenerative Medicine (CIRM) funded USD 3.9 million to Ankasa Regenerative Therapeutics to develop the treatment for spinal degeneration which can cause chronic, progressive back pain.
  • The growth of the market is driven by the increasing number of product launches in the global cell counting devices market. Recently, in January 2019 the DeNovix Inc. launched CellDrop Cell Counting without Slides.
  • The cell counting market growth is supported by Increased R&D expenditure in the healthcare industry.
  • Increasing number of stem cell organizations globally support the growth of the market.
  • Rising incidence & prevalence of cancer will support the growth of the market.
Market Restraints
  • The high cost of devices and product recalls are likely to hamper the growth of the cell counting market during the forecast period. Recently in May 2019, Beckman Coulter Inc. recalled DxH800 and DxH600 and DxH 900 hematology analyzers due to risk of inaccurate results.
Cell Counting Market Segmentation
By Product
  • Consumables: The consumables segment includes reagents, assay kits, microplates, and others. The instruments are further segmented into reagents, assay kits, microplates, and others. This segment holds the largest share in the cell counting market due to repeating purchase of consumable products.
  • Instruments: Instruments are used in cell counting methods. The instruments are further segmented into spectrophotometers, flow cytometers, hematology analyzers, and cell counters. Increasing number of product launches will support the growth of the market. Recently in April 2019, the Nexcelom Bioscience LLC launched Cellaca MX automated cell counter.
By Application
  • Research Application: Cell counting is used for research applications for discovering new medicines. Cell counting has the main application in stem cell research to develop advanced therapy for various diseases. This segment holds the largest share in the cell counting market.
  • Clinical & Diagnostic Applications: Cell counting has a significant role in clinical and diagnosis applications. It is used for diagnosis of various kinds of blood disorders, including infection, anemia, and leukemia.
  • Others: Others include industrial and other commercial applications.
By End-User
  • Pharmaceutical & Biotechnology Companies: The largest segment, pharmaceutical, and biotechnology companies, primarily use cell counting for research purposes. In 2018, the pharmaceutical and biotechnology companies segment held the largest share of the market.
  • Hospitals: Hospitals used cell counting products for the diagnosis of various kinds of diseases such as blood disorders and malaria, among others.
  • Research Institutes: These re involved in specific research activities to develop new and advance treatment for various diseases. Stem cell research institutes are major consumers for cell counting products.
  • Others: These include academic institutes, among others.
By Region
  • Americas: The Americas dominates the global cell counting market owing to an increase in the incidence of cancer, the presence of well-established pharmaceutical and biotechnology industry, availability of technologically advanced products, and significant support from the government in the form of funds and grants.
  • Europe: The key factors driving the market growth are the growing research and development funding and support by government bodies for the healthcare sector, the presence of major manufacturers, and growing healthcare expenditure, among others.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the cell counting market. This is due to developing healthcare infrastructure and rising drug development researchers.
  • Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Key Players
  • Thermo Fisher Scientific (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Logos Biosystems, Inc. (South Korea)
  • Olympus Corporation (Japan)
  • Agilent Technologies, Inc. (US)
  • PerkinElmer, Inc. (US)
  • Sysmex Corporation (Japan)
  • Abbott Laboratories (US)


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Global Medical Drones Market Growth Factors, Types and Application by Regional Analysis 2025

Market Forecast
Medical Drones’ Market is expected to worth USD 398 Million by 2025 and is anticipated to register a CAGR of 24.4% during the forecast period (2019 to2025).
Market Synopsis
Medical drones help in the transport of medical supplies such as vaccines, medications, and medical aids. These drones are deployed in remote or inaccessible areas for the rapid & secure distribution of medical supplies and the war-torn regions from medical facilities. Rising public acceptance of medical drone is also driving the growth in medical drones market demand.
Medical Drones Market, In recent years, has been seeking the attention of healthcare providers and governments to offer better healthcare services to remote locations. These drones help in on-time delivery of vaccines, medication, blood, and supplies to the origin and thereby reduce the outbreaks of life-threatening infectious diseases.
How can this technology help in improving safety and care delivery?
  • Bedside medication delivery
  • Effective treatment from the distance
  • Easy reach to an isolated place
  • Pre-treatment facility till the time emergency service arrives at takeover
Most of the key players in the market are focusing on developing medical drones to deliver medical supplies to far distances. For instance, in 2016, a Nevada based start-up Flirtey delivered medical test materials and supplies to and from an offshore vessel. This was the first successful ship to shore delivery in the U.S.
Market Influencer
Increasing investments by key players in R&D is the key factor driving the growth of the Global Medical Drones’ Market.
Market Drivers
  • Rising participation of Governments in various countries: Active involvement of local governments towards the deployment of drone service to remote and isolated areas is boosting the growth of the market. For instance, in 2018, the government of Ghana has signed an agreement with Zipline (US) for the deployment of drones throughout the country to provide medical supplies to untapped regions
  • Increasing application of drone for the supply of medical products such as blood, pharmaceuticals/drugs, and vaccines are anticipated to propel the market growth during the forecast period
  • Technological advancements to improving the accuracy of medical drones during emergency cases backed by R&D activities by key players
Market Restraints
  • Medical drones. Medical drones are not allowed to fly without the permission of the government. Thus, product approval laws are expected to restrict the growth of the medical drone’s market during the forecast period.
Segmentation
By Application
  • Blood Transfer: Rising incidence of severe bleeding deaths is boosting the demand for medical drones. The blood transfer segment is anticipated to show a growth rate of ~24% during the analysis period. According to the MRFR analysis, each year, around 60,000 Americans die from blood loss or hemorrhaging. Moreover, around 2 million people die across the globe.
  • Pharmaceutical/Drugs Transfer: The increasing focus of key medical drones vendors towards the development of drones for medication delivery is boosting the growth of this segment.
  • Vaccines Transfer: This segment is mainly on the drones that are associated with the delivery of the vaccine.
By End-User
  • Emergency Medical Services: This segment held the largest market share in 2018, owing to continues advancements in technology. For instance, in 2019, an automated drone’s delivery company Zipline (US), has planned for the expansion of a medical drone network into Ghana for emergency services.
  • Blood Banks: Owing to poor road conditions, transporting blood in underdeveloped countries is a huge task. Medical drones carry blood, plasma, and platelets from blood banks to remote hospitals and clinics.
By Region
  • Americas: The Americas held the largest regional market in 2018, owing to rising technology advancement. Moreover, the governments in this region are also promoting the acceptance of medical drones, as a result, players are aggressively working to develop advanced drones. In October 2019, United Parcel Services (US) received an authority from the Federal Aviation Administration to deliver medical packages at hospitals across the country.
  • Europe: The European market is expected to be the second-largest market in 2025. The market growth in this region can be attributed to government funding and support to the healthcare sector, coupled with increasing research and development.
  • Asia-Pacific: Asia-Pacific is the fastest-growing region for the medical drones market owing to the improving healthcare infrastructure, rising investments in healthcare, and expansions by market players in the region. Also, countries such as India and China are expected to be the fastest-growing in the region due to the focus of governments towards the adoption of new technologies and faster adoption of best treatment options from developed countries.
  • Middle East & Africa: It is projected to account for the least share of the global market due to an underdeveloped healthcare sector.
Key Players
  • DJI (China)
  • DHL (Germany)
  • Embention (Spain)
  • Flirtey (US)
  • Matternet (US)
  • Vayu (US)
  • Zipline (US)
  • EHang (China)
  • TUDelft (Netherlands)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Thalassemia Treatment Market Size, Share Analysis, Strategies, Revenue and Forecasts to 2025

Thalassemia Treatment Market is expected to cross USD 3763 Million by 2025 at a CAGR of 10.4%.
Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.
Market Synopsis
Thalassemia Treatment Market analysis asserts that, Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.
Market Influencers
Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the market.
Market Drivers
  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.
  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.
  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the market.
  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.
Market Restraints
  • Stringent regulatory policies
  • High treatment costs
Segmentation
By Type
  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.
  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.
By Treatment
  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.
  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.
  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.
  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.
  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the market growth in this segment.
By End-User
  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.
  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.
  • Others: This segment includes research laboratories, educational institutes, among others.
By Region
  • Americas: The largest growing regional market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.
  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.
  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.
  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.
Key Players
  • Novartis AG (Switzerland)
  • Bluebird Bio, Inc. (US)
  • Kiadis Pharma (Netherlands)
  • CELGENE CORPORATION (US)
  • Sangamo Therapeutics (US)
  • Acceleron Pharma, Inc. (US)
  • Gamida Cell (Israel)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Global Cardiac Biomarkers Market Set for Big Growth - Foresight by 2025

Market Forecast
Cardiac Biomarkers Market is expected to cross USD 4236.02 Million by 2025 at a CAGR of 16.36%.
Cardiac biomarkers are protein molecules released into the bloodstream from heart muscle damaged by a blocked artery. These enzymes are measured to have an idea of how much muscle damage has been done. These biomarkers are specially used to help diagnosis, evaluate, and monitor patients with suspected acute coronary syndrome (ACS).
The increasing prevalence of cardiovascular diseases is expected to drive the growth of the global Cardiac Biomarkers Diagnostics Market Trends. Out of the 17 million premature deaths due to noncommunicable diseases in 2015, 82% were in low- and middle-income countries, and 37% were caused by cardiovascular diseases.
Market Synopsis
Tests for cardiac biomarkers are used to diagnose acute coronary syndrome (ACS) and cardiac ischemia, conditions associated with insufficient blood flow to the heart. These biomarkers are also helpful in determining a person's risk of these conditions and also helps monitor and manage someone with ACS and cardiac ischemia.
Troponin T and I, CK-MB, and myoglobins are most commonly in the evaluation of acute coronary syndrome. Out of this troponin T and I are the markers of choice for detecting the heart damage. However, other cardiac biomarkers are less specific for heart and may be elevated in other conditions like severe muscle injury, liver disease, and kidney disease.
The increasing incidence of cardiac diseases and related conditions are strongly motivating market players to introduce new efficient technologies in the market.
Market Influencers
High prevalence of cardiac disorders and increasing participation of market players are actively facilitating the growth of the cardiac biomarkers market. In September 2019, Abbott received FDA clearance for ARCHITECT STAT High Sensitivity Troponin-I blood test. This troponin diagnostic test will be used to detect heart attacks faster and more accurately than contemporary troponin tests.
Market Drivers
  • High prevalence of raised blood pressure: Raised blood pressure is the leading risk factor for cardiovascular disease. The prevalence of this troponin T blood pressure in adults aged 18 years and over was around 24.1% in men and 20.1% in women in 2015
  • Increasing adoption of outsourcing services
  • Growing technological advancements:
  • High spending by the pharmaceutical industry
  • The increasing popularity of POC cardiac testing kits
  • Increasing affordability for advanced cardiac treatments
Market Restraints
  • Chances of false diagnosis of myocardial infarction
  • High cost of the procedure
  • Presence of other efficient methods for the diagnosis of cardiovascular diseases
Cardiac Biomarkers Market Segmentation
By Type
  • Myocardial muscle Creatine Kinase (CK-MB): CK-MB has been the gold standard for detecting myocardial necrosis. After myocardial infarction, elevated CK-MB levels appear within 3- 8 hours, peaking within 9-30 hours and levels return to normal after 48- 72 hours
  • Troponins (T and I): The most important characteristic of this biomarker is its apparent absolute cardiac specificity. Among patients with acute coronary syndromes, troponins level has been reported to provide prognostic information useful for the early identification of patients with an elevated risk of unstable angina progressing to AMI and death
  • Myoglobin: Myoglobin is a low molecular weight heme protein is rapidly released into the circulation and is the first marker to exhibit raising levels after myocardial infarction
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP: This biomarker is secreted primarily by the ventricular myocardium in response to wall stress. It is a very useful prognostic indicator in acute coronary syndrome
  • Ischemia Modified Albumin (IMA): This novel marker is produced when circulating serum albumin contacts ischemic heart tissues. IMA can be measured by the Albumin Cobalt Binding assay that is based on IMA's ability to bind to cobalt.
By Location of Testing
  • Point of Care Testing: Point of care testing expected to witness significant growth in the forecast period due to its increasing popularity
  • Laboratory Testing: Laboratory testing segment dominated the global cardiac biomarkers market. Increasing demand for cardiovascular disease diagnostics is boosting the revenue of this segment
By Application
  • Acute Coronary Syndrome: This segment holds the largest share owing to the increasing cases of this condition. It is a medical emergency that requires prompt diagnosis and care.
  • Congestive Heart Failure: It is a chronic progressive condition that affects the pumping power of your heart muscles
  • Myocardial Infarction: Approximately 1.5 million cases of myocardial infarction occur annually in the US region.
  • Atherosclerosis: Atherosclerosis is a disease in which plaque builds up inside your arteries. Cardiac troponins are used to assess the prognosis of patients presenting with atherosclerosis
By Region
  • Americas: The largest regional market. High prevalence of cardiac diseases is strongly expanding the US cardiac biomarkers market. As per the data suggested by the Centers for Disease Control and Prevention (CDC), around 610,000 people die of heart disease in the US every year. Also, coronary heart disease (CHD) is the most common type of heart disease, killing over 370,000 people annually.
  • Europe: Europe has some of the best healthcare services in the world, and rising participation of market players is strongly boosting the Europe cardiac biomarkers market. For instance, in October 2019, Novartis received FDA approval for Entresto for the treatment of symptomatic heart failure in pediatric patients aged one year and older.
  • Asia-Pacific: The fastest-growing regional market for Cardiac Biomarkers, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. Rising affordability for the advanced cardiac treatments and increasing disposable incomes are strongly impacting the growth of the Cardiac Biomarkers market in the region
  • Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the market growth over the forecast period.
Key Players
  • Abbott Laboratories (US)
  • ACS Biomarker (The Netherlands)
  • BD (Becton, Dickinson and Company) (US)
  • bioMérieux SA (France)
  • Bio-Rad Laboratories, Inc. (US)
  • Danaher Corporation (US)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Johnson and Johnson (US)
  • Quidel Corporation (US)
  • Randox Laboratories Limited (UK)
  • Siemens AG (Germany)
  • Thermo Fisher Scientific, Inc. (US)
  • Trivitron Healthcare Pvt. Ltd. (India)
  • Novartis (Switzerland)
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

The STD Testing Devices Market Grows Incredibly; Confirms MRFR Unleashing Industry Prognostications Up To 2025

Market Forecast
STD Testing Devices Market Share accounted for USD 70.29 Billion in 2018 and is expected to register a CAGR of 9.3% during the forecast period.
Market Synopsis
Sexually transmitted disease (STDs) is an infection caused due to some organisms. STDs can be transmitted from one person to another through sexual activity and intimate contact. The cases of sexually transmitted diseases keep climbing among 45 and older Americans. 82,938 cases of gonorrhea, syphilis, and chlamydia were reported among 45 and older Americans in the year 2016.
Market Influencer
The increasing prevalence of lifestyle diseases, rising geriatric population along with increasing awareness about sex-related diseases is influencing the market growth positively. The increasing number of product launches by key players in the market are likely to act as a promising factor for the increase in the near future.  For Instance, Quest Diagnostics launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.
Market Drivers
  • Increase in prevalence of sex-related diseases
    • Every year, 376 million new cases of chlamydia, syphilis, gonorrhea, and trichomoniasis are reported globally. The total estimated direct cost of STIs annually in the U.S. is about USD 16 billion.
    • The most common STIs affecting a lot of people are Chlamydia, gonorrhea, and syphilis. Approximately 1.5 million cases of chlamydia were reported in 2015 in US alone which represents it to be the highest number of annual cases of any condition ever reported.
    • A total of 89,239 cases of gonorrhea were reported by 27 states of the European Union in 2017.
  • Increasing prevalence of lifestyle diseases
  • Rise in healthcare expenditure
  • Increasing geriatric population
  • Increasing mergers & acquisitions by prominent players in the market
    • For instance, in 2019, the US Food and Drug Administration (FDA) has cleared two tests "The Aptima Combo 2 Assay (Hologic Inc) and the Xpert CT/NG (Cepheid)" to detect Chlamydia trachomatis and Neisseria gonorrhoeae from throat and rectum samples.
  • Increasing awareness about STIs
Market Restraints
  • Lack of information about the symptoms and causes is hampering the growth of the market.
Segmentation
By Type
  • Laboratory Devices: It is expected to hold a larger share. Laboratory devices are the traditional methods of detecting STI and a large number of hospitals and clinics are expected to be using the laboratory devices.
  • Point of Care (POC) Devices: It is expected to be the fastest-growing segment as it is less time-consuming.
By End-User
  • Hospitals and Clinics: Hospitals and clinics segment dominates the global market for The positive growth of hospitals is attributed to factors such as high volume of STD tests performed in hospital-based laboratories across the globe and growing patient population.
  • Diagnostic Laboratories: Diagnostic Laboratories segment take up the second-largest share due to the rising number of diagnostic labs and the increasing patient population.
  • Research Laboratories and Institutes: segment is projected to be the fastest-growing segment over the assessment period. The research and development activities with respect to STD diagnostics and treatment have increased in last decade which has resulted in the growing demand for the devices and kits in the R&D facilities. Besides that, government funding for the research and development for effective treatment of STD has pushed the growth of this segment. The researchers from King's College London, have published a study in Nature Communications, according to them skin vaccination can generate protective CD8 T-cells that are recruited to the genital tissues and could be used as a vaccination strategy for sexually transmitted infections (STIs).
By Region
  • Americas: It is the largest regional market owing to the factors such as large patient population, rise in prevalence of STIs, the availability of a wide variety of STD testing kits and surges in awareness about the causes of STIs and its treatments which are driving the growth of the market in this region.
    • According to the Centers for Disease Control and Prevention (CDC), more than 1300 cases of congenital syphilis, about 40% increase was reported in newborns during 2017-2018 in US. Similarly, a rise in 8487 new cases of women suffering from gonorrhea in US alone was reported during the year 2017-2018.
  • Europe: The key factors driving the market growth are the growing research and development support by government bodies for the healthcare sector, and the significant demand for STI testing is driving the growth of the STI testing devices market in Europe. Additionally, the rising initiatives by organizations are driving market growth. For Instance, EuroTEST initiative is a platform for information exchange and activities to improve early diagnosis and care of HIV, viral hepatitis, sexually transmitted infections, and tuberculosis.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global STI testing devices market. The rising patient population is driving the growth of the Asia-Pacific STI testing devices market. Additionally, increasing disposable income of the middle-class population, and improving healthcare infrastructure in emerging countries such as China and India are driving the market growth. However, unfavorable healthcare reforms may restrain the growth of the market to some extent.
  • Middle East & Africa: This region is the smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • Abbott (US)
  • MedMira Inc. (Canada)
  • Qaigen Inc. (US)
  • Thermo Fisher Scientific (US)
  • Cepheid (Danaher Corporation) (US)
  • Hoffmann-La Roche AG (Switzerland)
  • Diasorin S.p.A (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • bioMeriuex (France)
  • Becton Dickinson and Company (US)
  • Hologic, Inc. (US)
  • GenePOC Inc. (Canada)
  • Meridian Bioscience (US)
  • OraSure Technologies (US)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Invisible Orthodontics Market strategies and competitive analysis, forecast till 2023

Market Forecast
Invisible Orthodontics Market reached a value of USD 2598.8 Million in 2018 and is expected to register a CAGR of 13.99% during the assessment period of 2019 to 2025.
Market Synopsis
With the evolving technological advancements in the dental field, the area of invisible orthodontics has gained extensive popularity. Bracket-less aligners, clear retainers, and invisible braces some of the examples of cutting-edge technologies which have been launched in recent years. The high incidence rate of dental diseases in the developing countries and the rising inclination towards the correction of teeth deformities are likely to fuel the growth of the invisible orthodontics market across the globe. For instance, in Brazil, approximately 1.4 million new orthodontic cases are reported every year. Therefore, the key players involved in the invisible orthodontics market are vigorously focusing on product approvals to expand their customer base and brace their position in the market.
Moreover, the field of dentistry is evolving day by day. Public, as well as private organizations, are focusing on catering to the changing needs of the customers in terms of providing demos, conducting campaigns and dental check-ups. Thus, the employment of such strategies will promise the growth of the invisible orthodontics substantially.
Market Influencer
Increasing support by regulatory authorities to the private and public companies, in terms of investment and product approvals, acts as a significant factor that contributes substantially to the growth of the invisible orthodontics market in the longer run.
Market Drivers
  • The increasing prevalence of dental diseases pushes the need for newer treatment options, indirectly fueling the growth of the invisible orthodontics market globally. For instance, 90% of Australians are experiencing tooth decay. Such a high occurrence rate pushes the patients to choose newer techniques and prevention methods, thus fueling the growth of the invisible orthodontics market.
  • Several established players, such as Align Technology, Inc., and Dentsply Sirona are actively involved in getting approvals from regulatory authorities for their products in the invisible orthodontics market. For instance, in March 2017, Align Technology, Inc. launched the Invisalign Teen with mandibular advancement, the first clear aligner solution for Class II correction in growing tween and teen patients. This elucidates the impression that such new approvals are sure to drive the growth of the invisible orthodontics market in the near future.
  • Partnerships and collaborations between key players and local players
  • Increasing technological improvements in the orthodontics industry
  • High investment in research and development for the development of efficient products
  • Growing awareness created by dental professionals and key players about the benefits of clear aligners among the patients
Market Restraints
  • Limitations of invisible orthodontic products. Products such as clear aligners require long treatment time, which is why some of the patients do not prefer these products. In addition, poor compliance of patients with the dentists’ instructions leads to other complications of using these aligners. This results in a decreased target audience which would be utilizing such products, indirectly curbing the growth of the market.
  • Grey market for dental distribution, in terms of illegal selling of products of low quality at a cheaper price
Segmentation
By Product Type
  • Clear Aligners: The clear aligners segment is further segmented into hard, medium, and soft. The hard aligners sub-segment held a market value of an approximate of USD 1,394 million in 2018. The clear aligners segment held the largest share in 2018 due to a number of product launches by key companies such as Align Technology, Inc., Danaher, and others.
  • Braces: This segment has been further divided into ceramic braces and lingual braces. The braces segment is expected to be the fastest-growing during the forecast period owing to the increased awareness about the benefits created by key companies by conducting campaigns and dental check-ups.
  • Clear Retainers: A clear retainer is molded perfectly to fit the new position of the teeth.
By Age Group
  • Below 15: Various companies are getting approvals of their products for adolescents. In March 2017, Align Technology, Inc. launched the Invisalign Teen clear aligner for teenagers. Such increasing initiatives by prominent players for the below 15 age group fuels the growth of this segment.
  • 16-35: People in this age group are highly affected by dental disorders, including bite issues, due to change in lifestyle in recent years. This huge patient pool acts as a perfect target audience for prominent players to develop their products. Thus, the16-35 segment is likely to be the fastest-growing segment during the forecast period.
  • Above 35: The increasing middle-aged and geriatric pool of population suffering from dental caries, weakening of gums, abnormal eruptions in the teeth, among others, are the key factors for the growth of the above 35 segment. The benefits of clear braces are becoming palpable as a growing number of adult patients are now pursuing dental care.
By Application
  • Excessive Spacing: Spacing may prevent the teeth from functioning properly and may also result in gum problems due to the lack of protection provided by the teeth. Therefore, companies are coming up with products for corrective measures and conducting workshops and campaigns to create awareness. Thus, this segment held a majority share in 2018.
  • Crowding: Crowding can either be the result of several other orthodontic problems, such as impacted teeth, and teeth that do not fall out naturally, among others.
  • Malocclusion: The market, based on malocclusion, has been segmented into open bite, deep bite, and crossbite. The malocclusion segment is expected to be the fastest-growing segment during the assessment period owing to the increasing number of patients suffering from crossbites and open bites. Moreover, companies such as Align Technology, Inc. has a portfolio of products which are primarily used for the treatment of malocclusion. Thus, such factors are fueling the growth of this segment.
  • Abnormal Eruptions: Abnormal eruption occurs when a tooth emerges through the gum in the wrong place.
  • Others: Other applications of invisible orthodontic products are for correcting overjets, underbites, and others.
By Region
  • Americas: Americas was the largest regional market in 2018, owing to the continuous activities such as acquisitions, and partnerships employed by prominent players in the major countries in America. For instance, in March 2018, Dentsply Sirona (US) announced the acquisition of OraMetrix (US), a leading industry provider of innovative 3D technology solutions in the field of orthodontics. With this, the company aims to strengthen its position in the American invisible orthodontics market.
  • Europe: The European region holds the second largest share as there is increasing support from regulatory authorities, as well as ample of distributors in the European countries. For instance, in December 2017, Institut Straumann AG (Switzerland) acquired Same Day Solutions (SDS), a dental distribution company in Portugal. This acquisition provided Straumann access to SDS’ customers, which added the sales power and has been helping in supporting the company’s operations in Portugal.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global invisible orthodontics market. Direct marketing initiatives by the manufacturers to consumers are playing a substantial role in increasing the target audience and thus increasing the market size in this region. Also, strategic joint ventures by key players are contributing to the growth of the market. For instance, in January 2019, Institut Straumann AG, a company based in Switzerland, entered into a strategic partnership with a Chinese company, Tianjin ZhengLi Technology Company Limited. With this, Institut Straumann AG obtained exclusive distribution rights in China for its clear aligners, and the company aims to leverage its strong marketing and distribution capabilities to penetrate the highly attractive Chinese market. Thus, such strategies are likely to fuel the growth of the Asia-Pacific invisible orthodontics market.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure. But, in the last few years, top companies operating in the invisible orthodontics market are involved in acquiring different local distributors in the Arabian region to gain foothold in the local markets.
Key Players
  • 3M (US)
  • Align Technology, Inc. (US)
  • Clarus Company (US)
  • ClearPath Healthcare Services (US)
  • Danaher Corporation (US)
  • Dentsply Sirona (US)
  • DynaFlex (US)
  • Henry Schein, Inc. (US)
  • Institut Straumann AG (Switzerland)
  • Ormco (US)

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:

Biosimulation Market 2023 – Market Size, Share, Trends Analysis and Growth Forecast

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Technology Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)